BerGenBio Adds Another Brick To AXL Inhibitor Bemcentinib’s AML Potential
Executive Summary
As the most advanced AXL inhibitor product in the global pipeline, BerGenBio’s bemcentinib has continued to show encouraging data in AML, following on from monotherapy trials last year.
You may also be interested in...
Coronavirus Update: Vertex, Pfizer And Others Disclose Trial Disruptions, Viatris Merger Delayed
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.
Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types
RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.
AML Paradigm Shift: Doctors Welcome Many New Approvals And Approaches
This year's ASH meeting reflected a peak of development success, with many new approvals and many more in the pipeline.